Just 10% of Teva's employees located in Israel

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR

The number of people employed by drug company Teva in Israel has halved since 2012.

In the 1980s, Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) was dubbed "the people’s stock" in Israel. The high weighting of the stock in the leading index on the Tel Aviv Stock Exchange meant that it was the one most commonly found in investment portfolios, and it could be said that every Israeli was invested in it directly or indirectly.

Even ten years ago, however, it was hard to regard Teva as the people’s stock any more, and other stocks have overtaken it in trading volume on the Tel Aviv Stock Exchange.

Teva’s current weighting in the Tel Aviv 35 Index is similar to that of Bank Leumi (TASE: LUMI), Israel Discount Bank (DSCT), and Bank Hapoalim (POLI), and lower than that of Nice Systems (TASE: NICE). At NIS 32.3 billion, Teva currently has the fifth highest market cap of the companies on the index, after Bank Leumi, Nice Systems, Bank Hapoalim, and ICL (Israel Chemical Industries) (TASE: ICL).

Teva reached an all-time high in the summer of 2015, buoyed by the euphoria set off by its report of the acquisition of Actavis Generics from Allergan for $40 billion. Teva’s share price rose to over $70, giving it a market cap of $61 billion.

The acquisition, led by the company’s CEO at the time Erez Vigodman, was perceived as a positive move that would help Teva to grow, despite the high leverage and the debt that the company took on to finance the deal. In the year following the deal, however, and even before it was completed, doubts started to arise about the high price Teva was paying.

In the end, the Actavis acquisition proved a real danger to Teva. Instead of fortifying the company’s position, it turned it into a company in financial difficulties, and doubt was cast on its ability to service its debt.

After Vigodman’s resignation/removal in early 2017, Teva looked for a CEO with standing who would save it. It eventually found Kare Schultz from Denmark, who introduced aggressive efficiency measures that included the layoffs of thousands of employees and an end to dividend distributions.

During Schultz’s tenure, Teva’s debt has reduced, but he has had to cope with other difficulties, headed by Teva’s exposure to expensive legal proceedings. The most important ones were in connection with the sale of addictive opioid painkillers and with price fixing in the US generic drugs market.

Schultz recently announced that he was bringing forward his retirement, and Teva has announced the appointment of Richard Francis as his replacement in the CEO job. In the past, Francis served as CEO of rival Sandoz.

In 2021, the company employed nearly 36,000 around the world, down from a peak of nearly 57,000 in 2016. Only about 10% of its employees, 3,600, are now in Israel, half the number employed in the country in 2012.

In the past few years, the proportion of Teva’s global workforce employed in Israel has been steadily falling. Nevertheless, in accordance with its memorandum and articles, Teva’s CEO runs the company from its Israeli headquarters. In addition, five of the company’s twelve senior managers are Israelis.

At any rate, since January 2018, Teva has been defined in the US as a US Domestic Issuer, and it is required to report as a US corporation. This is because the completion of the acquisition of Actavis in 2016 led to a situation in which more than 50% of its assets were located in the US.

Published by Globes, Israel business news - en.globes.co.il - on December 11, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR
Orit Strook  credit: Marc Israel Sellem/The Jerusalem Post Finance C'ttee approves NIS 300m coalition funds distribution

The money will mainly go to Religious Zionist party minister Orit Strook's Ministry of Settlements and National Missions.

Dangoor Academy  credit: British Embassy in Tel Aviv British Embassy showcases Israeli healthcare startups

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

NextVision Stabilized Systems  credit: Shlomi Yosef/Tali Bogdanovsky Next Vision shareholders make NIS 230m exit

A British hedge fund has bought a 2.5% stake in the stabilized cameras company.

Energean CEO Mathios Rigas at the Israel Business Conference   credit: Shlomi Yosef Energean's $1b gas fields sale at risk

The sale of the energy company's asset portfolio in Egypt, Italy and Croatia may fall through because of the buyer's difficulties with the Italian regulator.

Kela Technologies founders Jason Manne, Hamutal Meridor, Alon Dror and Omer Bar Ilan  credit:  Yosef Haim Alterman Defense tech co Kela raises $39m

In response to the events of October 7, Kela has developed a platform for rapid integration of commercial technologies into military systems.

Benjamin Netanyahu  credit: ‎Alex Kolomoisky, Yediot Aharonot Firing the Shin Bet chief: The hurdles

Prime Minister Benjamin Netanyahu says he has "lost trust" in Shin Bet head Ronen Bar. Will this be enough to overcome legal challenges to his dismissal?

Emiliano Calemzuk  credit: PR CEO and "investor group" buying out Reshet 13

CEO Emiliano Calemzuk and the other investors will hold 74% of the television channel, while Len Blavatnik’s Access Industries and WBD will remain with 26%.

Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018